Use of a systems model of drug-induced liver injury (DILIsym®) to elucidate the mechanistic differences between acetaminophen and its less-toxic isomer, AMAP, in mice

Toxicology Letters

Volumn 226, Issue 2, 2014, Pages 163-172

  Howell, Brett A ^a   Siler, Scott Q ^a   Watkins, Paul B ^a  

^a HAMNER INSTITUTES FOR HEALTH SCIENCES   (United States)

Author keywords

Acetaminophen; AMAP; Drug induced liver injury (DILI); Hepatotoxicity; Mechanistic model; Mice; Paracetamol; Pharmacokinetic pharmacodynamic (PKPD) model; Reactive metabolite; Simulation

Indexed keywords

CYTOCHROME P450 INHIBITOR; METACETAMOL; PARACETAMOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPARATIVE STUDY; DRUG ABSORPTION; DRUG CONJUGATION; DRUG GLUCURONIDATION; DRUG METABOLISM; HYPOTHESIS; LIVER CELL; LIVER TOXICITY; MALE; MATHEMATICAL MODEL; METABOLITE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; SULFATION; TOXIC HEPATITIS;

ACETAMINOPHEN; AMAP; DRUG INDUCED LIVER INJURY (DILI); HEPATOTOXICITY; MECHANISTIC MODEL; MICE; PARACETAMOL; PHARMACOKINETIC/PHARMACODYNAMIC (PKPD) MODEL; REACTIVE METABOLITE; SIMULATION;

ACETAMINOPHEN; ACETANILIDES; ANIMALS; BENZOQUINONES; BIOTRANSFORMATION; COMPUTER SIMULATION; CYTOCHROME P-450 CYP2E1; DRUG-INDUCED LIVER INJURY; IMINES; ISOMERISM; LIVER; MICE; MODELS, BIOLOGICAL; SYSTEMS BIOLOGY;

EID: 84896040442     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2014.02.007     Document Type: Article

References (56)

1. Bauman J.N., Kelly J.M., Tripathy S., Zhao S.X., Lam W.W., Kalgutkar A.S., Obach R.S. Can in vitro metabolism-dependent covalent binding data distinguish hepatotoxic from nonhepatotoxic drugs? An analysis using human hepatocytes and liver S-9 fraction. Chem. Res. Toxicol. 2009, 22:332-340.
2. Bhattacharya S., Shoda L.K.M., Zhang Q., Woods C.G., Howell B.A., Siler S.Q., Woodhead J.L., Yang Y., McMullen P., Watkins P.B., Andersen M.E. Modeling drug- and chemical-induced hepatotoxicity with systems biology approaches. Front. Physiol. 2012, 3:462.
3. Birge R.B., Bartolone J.B., McCann D.J., Mangold J.B., Cohen S.D., Khairallah E.A. Selective protein arylation by acetaminophen and 2,6-dimethylacetaminophen in cultured hepatocytes from phenobarbital-induced and uninduced mice. Relationship to cytotoxicity. Biochem. Pharmacol. 1989, 38:4429-4438.
4. Bleibel W., Kim S., D'Silva K., Lemmer E.R. Drug-induced liver injury: review article. Dig. Dis. Sci. 2007, 52:2463-2471.
5. Brown R.P., Delp M.D., Lindstedt S.L., Rhomberg L.R., Beliles R.P. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Ind. Health 1997, 13:407-484.
6. Burke A.S., MacMillan-Crow L.A., Hinson J.A. Reactive nitrogen species in acetaminophen-induced mitochondrial damage and toxicity in mouse hepatocytes. Chem. Res. Toxicol. 2010, 23:1286-1292.
7. Corsini A., Ganey P., Ju C., Kaplowitz N., Pessayre D., Roth R., Watkins P.B., Albassam M., Liu B., Stancic S., Suter L., Bortolini M. Current challenges and controversies in drug-induced liver injury. Drug Saf. 2012, 35:1099-1117.
8. Dai G., He L., Chou N., Wan Y.-J.Y. Acetaminophen metabolism does not contribute to gender difference in its hepatotoxicity in mouse. Toxicol. Sci. 2006, 92:33-41.
9. Davern T.J., James L.P., Hinson J.A., Polson J., Larson A.M., Fontana R.J., Lalani E., Munoz S., Shakil A.O., Lee W.M. Measurement of serum acetaminophen-protein adducts in patients with acute liver failure. Gastroenterology 2006, 130:687-694.
10. Fernández-Checa J.C., Kaplowitz N., García-Ruiz C., Colell A., Miranda M., Marí M., Ardite E., Morales A. GSH transport in mitochondria: defense against TNF-induced oxidative stress and alcohol-induced defect. Am. J. Physiol. 1997, 273:G7-G17.
11. Gandelman K., Zhu T., Fahmi O.A., Glue P., Lian K., Obach R.S., Damle B. Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism. J. Clin. Pharmacol. 2010.
12. Geenen S., du Preez F.B., Reed M., Nijhout H.F., Kenna J.G., Wilson I.D., Westerhoff H.V., Snoep J.L. A mathematical modelling approach to assessing the reliability of biomarkers of glutathione metabolism. Eur. J. Pharm. Sci. 2012, 46:233-243.
13. Hadi M., Dragovic S., van Swelm R., Herpers B., van de Water B., Russel F.G.M., Commandeur J.N.M., Groothuis G.M.M. AMAP, the alleged non-toxic isomer of acetaminophen, is toxic in rat and human liver. Arch. Toxicol. 2012.
14. Halmes N.C., Samokyszyn V.M., Hinton T.W., Hinson J.A., Pumford N.R. The acetaminophen regioisomer 3'-hydroxyacetanilide inhibits and covalently binds to cytochrome P450 2E1. Toxicol. Lett. 1998, 94:65-71.
15. Hamilton M., Kissinger P.T. The metabolism of 2- and 3-hydroxyacetanilide. Determination of metabolic products by liquid chromatography/electrochemistry. Drug Metab. Dispos. 1986, 14:5-12.
16. Harrill A.H., Watkins P.B., Su S., Ross P.K., Harbourt D.E., Stylianou I.M., Boorman G.A., Russo M.W., Sackler R.S., Harris S.C., Smith P.C., Tennant R., Bogue M., Paigen K., Harris C., Contractor T., Wiltshire T., Rusyn I., Threadgill D.W. Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans. Genome Res. 2009, 19:1507-1515.
17. Hayashi P.H., Watkins P. Progress in our understanding of severe drug-induced liver injury. Liver Transpl. 2009, 15:675-676.
18. Hinson J.A., Roberts D.W., James L.P. Mechanisms of acetaminophen-induced liver necrosis. Handb. Exp. Pharmacol. 2010, 369-405.
19. Holme J.a., Hongslo J.K., Bjørge C., Nelson S.D. Comparative cytotoxic effects of acetaminophen (N-acetyl-p-aminophenol), a non-hepatotoxic regioisomer acetyl-m-aminophenol and their postulated reactive hydroquinone and quinone metabolites in monolayer cultures of mouse hepatocytes. Biochem. Pharmacol. 1991, 42:1137-1142.
20. Howell B.A., Chauhan A. A physiologically based pharmacokinetic (PBPK) model for predicting the efficacy of drug overdose treatment with liposomes in man. J. Pharm. Sci. 2010, 99:3601-3619.
21. Howell B.A., Yang Y., Kumar R., Woodhead J.L., Harrill A.H., Clewell H.J., Andersen M.E., Siler S.Q., Watkins P.B. In vitro to in vivo extrapolation and species response comparisons for drug-induced liver injury (DILI) using DILIsym™: a mechanistic, mathematical model of DILI. J. Pharmacokinet. Pharmacodyn. 2012, 39:527-541.
22. Johnson T.N., Boussery K., Rowland-Yeo K., Tucker G.T., Rostami-Hodjegan A. A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin. Pharmacokinet. 2010, 49:189-206.
23. Kaplowitz N., DeLeve L.D. Drug-induced Liver Disease 2013, Academic, Oxford.
24. Lam T.N., Hunt C.A. Discovering plausible mechanistic details of hepatic drug interactions. Drug Metab. Dispos. 2009, 37:237-246.
25. Larson A.M., Polson J., Fontana R.J., Davern T.J., Lalani E., Hynan L.S., Reisch J.S., Schiødt F.V., Ostapowicz G., Shakil A.O., Lee W.M. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005, 42:1364-1372.
26. Lee J.K., Abe K., Bridges A.S., Patel N.J., Raub T.J., Pollack G.M., Brouwer K.L.R. Sex-dependent disposition of acetaminophen sulfate and glucuronide in the in situ perfused mouse liver. Drug Metab. Dispos. 2009, 37:1916-1921.
27. Lee W.M. Drug-induced hepatotoxicity. N. Engl. J. Med. 2003, 349:474-485.
28. Lee W.M. Acetaminophen-related acute liver failure in the United States. Hepatol. Res. 2008, 38:S3-S8.
29. Lu S.C. Regulation of hepatic glutathione synthesis: current concepts and controversies. FASEB J. 1999, 13:1169-1183.
30. Lu S.C., Ge J.L., Kuhlenkamp J., Kaplowitz N. Insulin and glucocorticoid dependence of hepatic gamma-glutamylcysteine synthetase and glutathione synthesis in the rat. Studies in cultured hepatocytes and in vivo. J. Clin. Invest. 1992, 90:524-532.
31. McGill M.R., Lebofsky M., Norris H.-R.K., Slawson M.H., Bajt M.L., Xie Y., Williams C.D., Wilkins D.G., Rollins D.E., Jaeschke H. Plasma and liver acetaminophen-protein adduct levels in mice after acetaminophen treatment: dose-response, mechanisms, and clinical implications. Toxicol. Appl. Pharmacol. 2013, 269:240-249.
32. McGill M.R., Williams C.D., Xie Y., Ramachandran A., Jaeschke H. Acetaminophen-induced liver injury in rats and mice: comparison of protein adducts, mitochondrial dysfunction, and oxidative stress in the mechanism of toxicity. Toxicol. Appl. Pharmacol. 2012, 264:387-394.
33. Michelson S., Sehgal A., Friedrich C. In silico prediction of clinical efficacy. Curr. Opin. Biotechnol. 2006, 17:666-670.
34. Nelson E.B. Method for analgesia using 3-hydroxyacetanilide. US4238508 A 1980.
35. Nelson E.B. The pharmacology and toxicology of meta-substituted acetanilide I: acute toxicity of 3-hydroxyacetanilide in mice. Res. Commun. Chem. Pathol. Pharmacol. 1980, 28:447-456.
36. Priyadarsiny P., Khattar S.K., Malik R., Udupa V., Seshaiah A., Rahman S., Shingatgeri V.M., Bora R.S., Saini K.S. Differential gene expression analysis of a known hepatotoxin, N-acetyl-p-amino-phenol (APAP) as compared to its non-toxic analog, N-acetyl-m-amino-phenol (AMAP) in mouse liver. J. Toxicol. Sci. 2008, 33:163-173.
37. Pumford N.R., Hinson J.A., Benson R.W., Roberts D.W. Immunoblot analysis of protein containing 3-(cystein-S-yl)acetaminophen adducts in serum and subcellular liver fractions from acetaminophen-treated mice. Toxicol. Appl. Pharmacol. 1990, 104:521-532.
38. Punt A., Paini A., Boersma M.G., Freidig A.P., Delatour T., Scholz G., Schilter B., van Bladeren P.J., Rietjens I.M.C.M. Use of physiologically based biokinetic (PBBK) modeling to study estragole bioactivation and detoxification in humans as compared with male rats. Toxicol. Sci. 2009, 110:255-269.
39. Rashed M.S., Myers T.G., Nelson S.D. Hepatic protein arylation, glutathione depletion, and metabolite profiles of acetaminophen and a non-hepatotoxic regioisomer, 3'-hydroxyacetanilide, in the mouse. Drug Metab. Dispos. 1990, 18:765-770.
40. Rashed M.S., Streeter A.J., Nelson S.D. Investigations of the N-hydroxylation of 3'-hydroxyacetanilide, a non-hepatotoxic positional isomer of acetaminophen. Drug Metab. Dispos. 1989, 17:355-359.
41. Roberts S.A., Price V.F., Jollow D.J. Acetaminophen structure-toxicity studies: in vivo covalent binding of a nonhepatotoxic analog, 3-hydroxyacetanilide. Toxicol. Appl. Pharmacol. 1990, 105:195-208.
42. Salminen W.F., Voellmy R., Roberts S.M. Differential heat shock protein induction by acetaminophen and a nonhepatotoxic regioisomer, 3'-hydroxyacetanilide, in mouse liver. J. Pharmacol. Exp. Ther. 1997, 282:1533-1540.
43. Senior J.R. Drug hepatotoxicity from a regulatory perspective. Clin. Liver Dis. 2007, 11:507-524. vi.
44. Shan X., Jones D.P., Hashmi M., Anders M.W. Selective depletion of mitochondrial glutathione concentrations by (R,S)-3-hydroxy-4-pentenoate potentiates oxidative cell death. Chem. Res. Toxicol. 1993, 6:75-81.
45. Shoda L., Kreuwel H., Gadkar K., Zheng Y., Whiting C., Atkinson M., Bluestone J., Mathis D., Young D., Ramanujan S. The Type 1 Diabetes PhysioLab Platform: a validated physiologically based mathematical model of pathogenesis in the non-obese diabetic mouse. Clin. Exp. Immunol. 2010, 161:250-267.
46. ®), a mechanistic mathematical model of drug-induced liver injury. Biopharm. Drug Dispos. 2014, 35:33-49.
47. Stamper B.D., Bammler T.K., Beyer R.P., Farin F.M., Nelson S.D. Differential regulation of mitogen-activated protein kinase pathways by acetaminophen and its nonhepatotoxic regioisomer 3'-hydroxyacetanilide in TAMH cells. Toxicol. Sci. 2010, 116:164-173.
48. Streeter A.J., Bjorge S.M., Axworthy D.B., Nelson S.D., Baillie T.A. The microsomal metabolism and site of covalent binding to protein of 3'-hydroxyacetanilide, a nonhepatotoxic positional isomer of acetaminophen. Drug Metab. Dispos. 1984, 12:565-576.
49. Tavoloni N., Berk P.D. Hepatic Transport and Bile Secretion: Physiology and Pathophysiology 1993, Raven Press.
50. Tirmenstein M.A., Nelson S.D. Subcellular binding and effects on calcium homeostasis produced by acetaminophen and a nonhepatotoxic regioisomer, 3'-hydroxyacetanilide, in mouse liver. J. Biol. Chem. 1989, 264:9814-9819.
51. Tirmenstein M.A., Nelson S.D. Acetaminophen-induced oxidation of protein thiols. Contribution of impaired thiol-metabolizing enzymes and the breakdown of adenine nucleotides. J. Biol. Chem. 1990, 265:3059-3065.
52. Vaccarino A.L., Paul D., Mukherjee P.K., Rodríguez de Turco E.B., Marcheselli V.L., Xu L., Trudell M.L., Minguez J.M., Matía M.P., Sunkel C., Alvarez-Builla J., Bazan N.G. Synthesis and in vivo evaluation of non-hepatotoxic acetaminophen analogs. Bioorg. Med. Chem. 2007, 15:2206-2215.
53. Watkins P.B. Idiosyncratic liver injury: challenges and approaches. Toxicol. Pathol. 2005, 33:1-5.
54. Watkins P.B. Drug safety sciences and the bottleneck in drug development. Clin. Pharmacol. Ther. 2011, 89:788-790.
55. Woodhead J.L., Howell B.A., Yang Y., Harrill A.H., Clewell H.J., Andersen M.E., Siler S.Q., Watkins P.B. An analysis of N-acetylcysteine treatment for acetaminophen overdose using a systems model of drug-induced liver injury. J. Pharmacol. Exp. Ther. 2012, 342:529-540.
56. Zhong Q., Putt D.A., Xu F., Lash L.H. Hepatic mitochondrial transport of glutathione: studies in isolated rat liver mitochondria and H4IIE rat hepatoma cells. Arch. Biochem. Biophys. 2008, 474:119-127.